Glaukos Corporation (NYSE: GKOS) is a Healthcare company in the Medical - Devices industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
161.42
-2.05-1.25%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -3.25 | Insider Own | 3.16% | Shs Outstand | 58.98M | Perf Week | -5.26% |
| Market Cap | 9.52B | Forward P/E | - | EPS next Y | 0.50 | Insider Trans | -9.46% | Shs Float | 56.62M | Perf Month | -12.34% |
| Enterprise Value | 9.34B | PEG | - | EPS next Q | -0.12 | Inst Own | - | Short Float | 6.75% | Perf Quarter | 26.69% |
| Income | -188.00M | P/S | 15.51 | EPS this Y | 90.56% | Inst Trans | - | Short Ratio | 4.38 | Perf Half Y | 56.38% |
| Sales | 614.00M | P/B | 13.96 | EPS next Y | 264.40% | ROA | -20.43% | Short Interest | 3.82M | Perf YTD | 42.96% |
| Book/sh | 11.56 | P/C | 33.29 | EPS next 5Y | - | ROE | -27.07% | 52W High | 191.62 -15.76% | Perf Year | 96.02% |
| Cash/sh | 4.85 | P/FCF | - | EPS past 3/5Y | - | ROIC | -9.59% | 52W Low | 73.16 120.64% | Perf 3Y | 110.15% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 21.45% 17.64% | Gross Margin | 79.12% | Volatility | 4.31% 3.57% | Perf 5Y | 192.96% |
| Dividend TTM | - | EV/Sales | 15.21 | EPS Y/Y TTM | -17.33% | Oper. Margin | -13.13% | ATR (14) | 6.92 | Perf 10Y | 420.88% |
| Dividend Ex-Date | - | Quick Ratio | 4.46 | Sales Y/Y TTM | 60.31% | Profit Margin | -30.68% | RSI (14) | 36.40 | Recom | 2.32 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.04 | EPS Q/Q | 41.67% | SMA20 | -8.88% | Beta | 0.67 | Target Price | 190.75 |
| Payout | 0.00% | Debt/Eq | 0.21 | Sales Q/Q | 50.00% | SMA50 | -5.48% | Rel Volume | 0.81 | Prev Close | 163.47 |
| Employees | 1,094 | LT Debt/Eq | 0.21 | Earnings | Nov 04 | SMA200 | 22.10% | Avg Volume | 796.18K | Price | 161.42 |
| IPO Date | Jun 25, 2015 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 33.50% 22.97% | Net Debt/EBITDA | 0.08 | Volume | 646,793 | Change | -1.25% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-20-26 | Reiterated | BTIG | Buy | $164 → $202 |
| Jul-30-26 | Reiterated | Stifel Nicolaus | Hold | $175 → $190 |
| Jul-30-26 | Reiterated | HC Wainwright & Co. | Buy | $168 → $195 |
| Jul-30-26 | Reiterated | Piper Sandler | Overweight | $165 → $195 |
| Jul-30-26 | Reiterated | Truist Securities | Buy | $180 → $215 |
| Jul-30-26 | Reiterated | Wells Fargo | Overweight | $135 → $178 |
| Jul-30-26 | Reiterated | Needham | Buy | $150 → $201 |
| Jul-16-26 | Reiterated | Truist Securities | Buy | $145 → $180 |
| Jul-13-26 | Reiterated | BTIG | Buy | $162 → $164 |
| Jul-06-26 | Initiated | H.C | Buy | $168 |
Latest News· Times ET
Sep-15-26
Sep-10-26
Sep-10-2608:00AM
Sep-01-26
Sep-01-2607:21AM
Aug-31-26
Aug-31-2612:29AM
Aug-28-26
12:26AM
Aug-25-26
Aug-23-26
Aug-23-2611:47PM
Aug-20-26
Aug-19-26
03:00AM
Aug-13-26
Aug-13-2612:19PM
Aug-04-26
Aug-04-2611:45PM
Company
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 614 | 507 | 383 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 128 | 114 | 94 | — | — | — | — | — | — | |
| Gross Profit | 485 | 393 | 289 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 387 | 329 | 263 | — | — | — | — | — | — | |
| Research and Development | 177 | 151 | 136 | — | — | — | — | — | — | |
| Other Operating Expense | 1 | 0 | 13 | — | — | — | — | — | — | |
| Operating Income | -80 | -87 | -122 | — | — | — | — | — | — | |
| Interest Expense | 4 | 5 | 10 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -107 | -102 | -13 | — | — | — | — | — | — | |
| Net Income Before Taxes | -193 | -193 | -146 | — | — | — | — | — | — | |
| Income Taxes | -5 | -5 | 1 | — | — | — | — | — | — | |
| Consolidated Net Income | -188 | -188 | -146 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -188 | -188 | -146 | — | — | — | — | — | — | |
| Net Income | -188 | -188 | -146 | — | — | — | — | — | — | |
| EPS (Recurring) | -3.25 | -3.28 | -2.77 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -3.25 | -3.28 | -2.77 | — | — | — | — | — | — | |
| EPS (Diluted) | -3.25 | -3.28 | -2.77 | — | — | — | — | — | — | |
| EBITDA | -142 | -146 | -96 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 15.25 | 12.69 | 20.75 | — | — | — | — | — | — | |
| Gross Margin | 78.99 | 77.51 | 75.46 | — | — | — | — | — | — | |
| Operating Margin | -13.03 | -17.16 | -31.85 | — | — | — | — | — | — | |
| Net Margin | -30.62 | -37.08 | -38.12 | — | — | — | — | — | — | |
| Shares Outstanding | 58 | 57 | 53 | — | — | — | — | — | — | |
| Market Capitalization | 9,362 | 6,436 | 7,947 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Navratil Tomas | CHIEF DEVELOPMENT OFFICER | Aug 28 '26 | Sale | 180.67 | 13,744 | 2,483,104 | 73,890 | Sep 01 |
| Kliman Gilbert H | Director | Aug 19 '26 | Option Exercise | 25.77 | 2,500 | 64,425 | 39,906 | Aug 20 |
| Kliman Gilbert H | Director | Aug 19 '26 | Sale | 190.00 | 2,500 | 475,000 | 37,406 | Aug 20 |
| Gilliam Joseph E | PRESIDENT & COO | Aug 11 '26 | Sale | 179.74 | 60,000 | 10,784,659 | 72,588 | Aug 13 |
| Gilliam Joseph E | PRESIDENT & COO | Aug 11 '26 | Option Exercise | 52.94 | 60,000 | 3,176,400 | 132,588 | Aug 13 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Aug 07 '26 | Option Exercise | 33.81 | 20,000 | 676,200 | 63,906 | Aug 11 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Aug 07 '26 | Sale | 180.13 | 20,000 | 3,602,600 | 43,906 | Aug 11 |
| WEN LEANA | Director | Jul 31 '26 | Sale | 167.63 | 525 | 88,006 | 21,092 | Aug 03 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Jul 16 '26 | Option Exercise | 38.68 | 10,000 | 386,800 | 53,906 | Jul 21 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Jul 16 '26 | Sale | 160.00 | 10,000 | 1,600,000 | 43,906 | Jul 21 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Jul 09 '26 | Sale | 155.00 | 10,000 | 1,550,000 | 43,681 | Jul 13 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Jul 09 '26 | Option Exercise | 38.68 | 10,000 | 386,800 | 53,681 | Jul 13 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Jul 06 '26 | Option Exercise | 38.68 | 10,000 | 386,800 | 53,681 | Jul 08 |
| Thurman Alex R. | SVP & CHIEF FINANCIAL OFFICER | Jul 06 '26 | Sale | 150.00 | 10,000 | 1,500,000 | 43,681 | Jul 08 |
| Navratil Tomas | CHIEF DEVELOPMENT OFFICER | Jul 01 '26 | Sale | 139.06 | 716 | 99,567 | 87,634 | Jul 08 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.